Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
IC

NYSE · ICUI

ICU Medical, Inc.

Healthcare · Medical - Instruments & Supplies

$152.65

Down-$0.26 (-0.17%)

Updated Sep 20, 2026, 11:40 AM

SID Score

5.1/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.63B
P/E ratio
-624.25
Dividend yield
0.00%
52-week range
$112.50 – $192.85
Volume
388.09K
Avg. volume
272.38K

Price performance

ICUI price history

1M range · 19 trading sessions · Daily adjusted prices

ICUI closed at $152.65 after 19 trading sessions, down 16.38% for the selected period.

Last close
$152.65
Period change
-16.38%
Period low
$152.65
Period high
$182.55
Daily close
View OHLC price history
ICUI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$151.67$153.30$151.3301$152.65388.09K
Sep 17, 2026$157.77$157.77$152.79$152.91204.4K
Sep 16, 2026$156.07$158.98$155.58$155.62193.64K
Sep 15, 2026$156.79$157.60$154.97$155.88196.46K
Sep 14, 2026$157.63$158.68$155.7438$157.60189.87K
Sep 11, 2026$160.33$162.155$155.48$156.48189.02K
Sep 10, 2026$159.46$160.335$155.905$157.26171.6K
Sep 9, 2026$160.89$166.595$159.32$161.00290.52K
Sep 8, 2026$166.06$166.59$160.06$160.89311.29K
Sep 4, 2026$165.30$167.87$164.80$167.58163.5K
Sep 3, 2026$171.69$171.69$165.58$166.29241.54K
Sep 2, 2026$171.23$174.05$169.66$169.85360.31K
Sep 1, 2026$173.13$176.43$170.42$170.81326.37K
Aug 31, 2026$173.66$174.875$169.38$172.95217.4K
Aug 28, 2026$175.45$177.68$174.10$175.10162.21K
Aug 27, 2026$177.49$179.07$174.88$175.10263.69K
Aug 26, 2026$182.80$182.84$179.18$179.59161.55K
Aug 25, 2026$182.53$183.245$180.65$182.24130.35K
Aug 24, 2026$184.39$185.00$180.26$182.55230.44K

Latest ICUI news

The latest Smart Investors Daily articles mentioning ICUI.

Stock researchCompany · Overview

ICUI research

Overview

Company profile and research snapshot.

Company profile

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$163.00
Implied upside
—
Analysts
—
ICUI recent ratings
DateFirmRatingTarget
Aug 7, 2026Piper SandlerOverweight—
Aug 7, 2026BTIGBuy—
Aug 7, 2026NeedhamBuy—
Jul 21, 2026KeybancOverweight—
Jun 15, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 27, 2026

ICU Medical to Participate in Upcoming Investor Conferences

SAN CLEMENTE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference on September 9-10, 2026 Company management will attend the Wells Fargo 21st Annual Healthcare Conference, held at the Encore Boston Harbor in Boston, MA, participating in one-on-one meetings on Wednesday, Sept

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By